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Abstract
Recombinant adeno-associated viral vectors (rAAV) are regarded as promising vehicles for 
therapeutic gene delivery. Continued development and new strategies are essential to improve the 
potency of AAV vectors and reduce the effective dose needed for clinical efficacy. In this regard, 
many studies have focused on understanding the cellular transduction mechanisms of rAAV, often 
with the goal of exploiting this knowledge to increase gene transfer efficiency. Here, we provide 
an overview of our evolving understanding of rAAV cellular trafficking pathways through the host 
cell, beginning with cellular entry and ending with transcription of the vector genome. Strategies 
to exploit this information for improving rAAV transduction are discussed.
Introduction
Gene therapy broadly describes strategies in which genetic material is introduced into a 
target cell in an effort to treat or cure disease. Of the approaches that are currently being 
explored, recombinant adeno-associated viral vectors (rAAV) have emerged as one of the 
most promising candidates. Adeno-associated virus (AAV) is a member of the parvoviridae 
family that was initially discovered as a contaminant in simian adenovirus preparations (1). 
A small, icosahedral non-enveloped virus ~25 nm in diameter that contains a single-stranded 
DNA genome (2), AAV is distinct from other members of the parvoviridae family due to its 
inability to replicate without the assistance of a helper virus, such as Adenovirus (Ad), 
Herpes simplex virus (HSV), human papilloma virus (HPV), or vaccinia virus (3). 
*Corresponding Author: Aravind Asokan, Ph.D., CB # 7352, Gene Therapy Center, 5123 Thurston Building, The University of North 
Carolina at Chapel Hill, Chapel Hill, NC 27599-7352, Tel. No: 919-843-7621, aravind@med.unc.edu. 
Conflict of Interest
Aravind Asokan is a co-founder at Stridebio LLC and an inventor on patents owned by UNC-CH.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Curr Opin Virol. Author manuscript; available in PMC 2017 December 01.
Published in final edited form as:
Curr Opin Virol. 2016 December ; 21: 54–60. doi:10.1016/j.coviro.2016.08.001.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Additionally, AAV can confer long term gene expression, has a range of serotypes that 
collectively have a range of tissue tropism, and can package any transgenes flanked by AAV 
inverted terminal repeats (ITRs) and with the total genome size not exceeding ~5 kb (4). All 
of these properties make AAV an excellent candidate for therapeutic gene delivery.
It is well known that eukaryotic mechanisms to sort and degrade internalized cargo are 
exploited by several viruses and pathogens for infecting and replicating within host cells. At 
the same time, several cellular factors act to restrict viral infection within the host. A similar 
dichotomy is apparent in case of rAAV, with host factors demonstrating the ability to aid or 
limit transduction efficiency. For instance, one study estimates that following cellular 
uptake, only ~30% of AAV particles will successfully reach the nucleus (5). Here, we review 
the cellular transduction mechanisms of rAAV vectors by breaking down the different steps 
leading to transgene expression. We also discuss strategies to overcome host restriction 
factors that act as barriers that limit the potential of rAAV-mediated gene therapy in the 
clinic.
Cellular Uptake of rAAV
The first step in AAV infection requires binding to cell surface glycan receptors(6). This key 
step mediates cell surface attachment of virions and triggers subsequent cellular 
internalization and trafficking leading to transduction. Cellular uptake of AAV particles into 
endocytic vesicles is thought to be mediated by integrins and/or different transmembrane 
receptors. However, our understanding of AAV receptor usage continues to evolve. Although 
it is currently unclear how different AAV serotypes exploit specific receptors for cellular 
uptake, it is well known that mammalian cells are known to internalize extracellular material 
by numerous endocytic pathways, several of which have been implicated in uptake of rAAV. 
The first studies to investigate AAV uptake suggested that internalization of rAAV occurred 
via clathrin-mediated endocytosis. In these studies, transduction of AAV2 was inhibited by 
expression of a dominant-negative mutant of dynamin, a protein necessary for successful 
clathrin-mediated endocytosis (7, 8). Additionally, internalized AAV2 colocalized with 
transferrin, a protein known to be internalized by this mechanism. It is also worth noting that 
transcytosis of rAAVs has been shown to occur in polarized cells in a serotype-dependent 
manner, and it has been suggested that this phenomenon is dependent upon caveolin (9).
A more recent study suggests that uptake of AAV2 is dependent on the clathrin-independent 
carriers and GPI-enriched endocytic compartment (CLIC/GEEC) endocytic pathway (10). 
This study demonstrated that AAV2 uptake was inhibited by dominant negative versions of 
Arf1, Cdc42, and GRAF1, three important effectors of the of the CLIC/GEEC pathway. In 
addition, AAV2 colocalized with cholera toxin B and GPI-anchored GFP, two markers of 
CLIC vesicles, after internalization. In addition, this study identified EIPA as an inhibitor of 
CLIC/GEEC endocytosis. However, it is worth noting that EIPA is classically known as an 
inhibitor of macropinocytosis. Consistently, other studies have suggested a role for 
macropinocytosis in rAAV uptake. One such study demonstrated that inhibition of Rac1 
activation, a key effector of macropinocytosis, inhibits AAV internalization (11). Another 
study used multiple small molecule inhibitors of macropinocytosis, including EIPA, to 
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demonstrate that inhibition of macropinocytosis decreased transduction in some cell types, 
while demonstrating enhanced transduction in others (12).
Although diverse endocytic mechanisms have been implicated in AAV cell entry, it is 
evident that certain uptake pathways lead to successful transduction, while other pathways in 
the same cells lead to a “dead end” for AAV (10, 11). Further, it is likely that such 
mechanisms are altered in a cell-type dependent manner (12).
Post-Entry Trafficking of rAAV
After rAAV enters the cell, it must traffic towards the nucleus in order to successfully deliver 
its genetic cargo. Immediately after uptake, AAV is presumably trafficked to Rab5+ early 
endosomal compartment, which is a feature conserved amongst many parvoviruses (13). 
From here, rAAV traffics through a number of different compartments. Studies have 
demonstrated that rAAV2 traffics through both Rab7+ late endosomes and Rab11+ recycling 
endosomes (14). As is the case with AAV cell entry, intracellular trafficking pathways likely 
differ in a cell line-dependent and serotype-dependent fashion. For instance, while rAAV9 
was localized to Rab5+, Rab7+, and Rab11+ vesicles in neurons in cell culture, this serotype 
was shown to only traffic effectively along axons in Rab7+ endosomes (15).
Vesicle-entrapped rAAV particles have been shown by numerous studies to traffic to the 
Golgi apparatus (16–18). One of the steps known to be required for efficient trafficking is 
endosome acidification, as the vacuolar H+-ATPase inhibitor bafilomycin A1 effectively 
blocks transduction (8, 19). Additionally, studies utilizing the small molecules brefeldin A 
and golgicide A, known to disrupt the Golgi apparatus, have shown that trafficking of rAAV 
through the Golgi apparatus is also required (19, 20). Recently, we demonstrated that 
inhibition of endoplasmic reticulum-associated degradation (ERAD) by eeyarestatin I (EerI) 
in HeLa cells reroutes rAAV to enlarged Lamp1+ lysosomes. This approach increased 
transduction, indicating that trafficking of rAAV through LAMP1+ vesicles may be an 
important step in infection (21). It is important to note that, as of now, no studies have 
observed rAAV localization within the endoplasmic reticulum (ER) or implicated a role for 
rAAV trafficking through the ER prior to nuclear entry.
At the molecular level, a recent study showed that siRNA-mediated knockdown of syntaxin 
5 (STX5), as well as disruption of STX5 by the small molecule Retro2.1, reduced rAAV 
transduction, suggesting that retrograde transport of rAAV to the trans-Golgi network (TGN) 
mediated by syntaxin 5 is important for transduction (20). Another recent study utilized a 
screen based on haploid cells and identified KIAA0319L as a cellular factor required for 
infection of cells by multiple AAV serotypes, which they termed AAV receptor (AAVR) 
(22). CRISPR-based technology was utilized to knockout AAVR both in vitro and in vivo to 
demonstrate that AAV infection is severely inhibited in the absence of AAVR, and can be 
rescued by subsequent complementation by expression of ectopic AAVR. Interestingly, 
AAVR largely localizes to the Golgi, and contains a signal in the C-terminus that results in 
dynamic recycling of AAVR from the cellular surface to the TGN. While the precise 
mechanisms underlying AAVR-mediated AAV transduction remain to be understood, the 
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data demonstrates that AAVR is an essential cellular factor that mediates AAV transport 
through the endomembrane system to the TGN for successful infection.
After trafficking of rAAV through the endomembrane system, rAAV escapes the endosome 
into the cytosol. Endosomal escape is dependent on a phospholipase A2 (PLA2) domain 
located in the VP1 unique region of AAV (23, 24). Multiple studies have shown that 
mutation or deletion of the PLA2 domain prevents endosomal escape and subsequent 
transduction (25). Thus, an absolutely essential outcome of these trafficking steps is the 
triggering of conformational changes in the capsid (26) leading to exposure of the N-
terminal domains of VP1 and VP2, which are buried inside the capsid prior to infection (27). 
Exposure of these domains for successful transduction is required, as it has been 
demonstrated that microinjection of both complete virions, as well as VP3-only virions, 
directly into the cytosol do not properly transduce the cell (28). It has been suggested that 
the AAV capsid has protease activity that is pH-dependent, which could possibly be 
triggered by the acidification of the endosome (29). However, it has yet to be determined if 
the self-cleavage events mediated by this activity also play a role in the exposure of the 
VP1/VP2 N-termini, or in other events related to transduction.
Nuclear Import of rAAV
After escaping the endosome into the cytosol, rAAV then must enter the nucleus, where it 
will undergo uncoating and deliver its genetic cargo. Nuclear entry of AAV has been 
proposed as a major rate-limiting step in the infectious pathway (8). Four basic regions 
(BR1-4) were identified on AAV2 that were conserved among serotypes 1–11, that were 
investigated for their potential function as nuclear localization signals (NLS). BR4 is located 
within VP3 and was shown to have no impact on nuclear import of rAAV virions, but 
mutation of BR4 did result in virion assembly defects (outside the focus of this review) (30). 
However, BR3, located within both VP1 and VP2, is essential for AAV transduction (28). In 
addition, BR1 and BR2, to a lesser extent, are also important for AAV transduction. 
However, confocal microscopy studies of BR-negative mutants demonstrated that BR2 and 
BR3 are important for nuclear translocation (17).
A recent study demonstrated that rAAV2 enters the nucleus through the nuclear pore 
complex (NPC) by blocking nuclear entry of rAAV2 with wheat germ agglutinin, a lectin 
that binds the NPC and blocks and cargo from traversing through (31). This study also 
demonstrated that importin-β1 is the host protein responsible for import of rAAV2 particles 
through the NPC. Capsid interaction with members of the importin-α family of proteins was 
also shown by co-IP, but their involvement in nuclear import of rAAV2 remains unclear. This 
route of nuclear translocation was further supported by live cell imaging technology that 
witnessed labeled rAAV2 particles traverse the nuclear envelope through labeled NPCs (32).
After nuclear entry, rAAV has been shown to traffic to the nucleolus. AAV capsids have been 
shown to interact with nucleophosmin and nucleoin, both of which localize to the nucleolus 
(33, 34). Interestingly, rAAV particles remain intact and infectious in the nucleolus, thereby 
indicating that the nucleolar compartment is not where the capsids uncoat and deliver their 
genetic payload. Instead, it appears that the capsids must egress out of the nucleolus and 
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move into the nucleoplasm in order to successfully transduce the cell. These observations 
are indirectly supported by small molecule and siRNA knockdown studies, which seem to 
suggest that nucleolar accumulation of rAAV is unfavorable for transduction (35). More 
investigation into possible differences in nucleolar accumulation between cell types and 
serotypes could help understand the role of the nucleolus in rAAV transduction.
Second-strand synthesis and transgene expression
After AAV reaches the nucleus, the viral capsid must uncoat/disassemble to release the 
packaged genome. The mechanisms underlying uncoating of AAV remain unclear, though it 
is known that genome composition may play an important role in uncoating and genome 
release (36). After uncoating, the virus must undergo conversion of the single-stranded DNA 
genome into its double-stranded form, a process involving second-strand DNA synthesis. 
This process has been shown to be a rate limiting step in infection in the absence of a helper 
virus (37), since second strand DNA synthesis is blocked by numerous host cellular factors 
critical for cellular DNA quality control. For instance, FKBP52 has been shown to bind the 
ITRs and blocks second-strand synthesis (38, 39). Additionally, the MRN complex, a 
cellular DNA damage-sensing complex consisting of the three cellular proteins Mre11, 
Rad50, and Nbs1, severely blocks AAV infection at the genome level (40–42). Furthermore, 
other proteins involved in the DNA damage response have been shown to interact with AAV 
genomes, such as Ku86 and Rad52, but the specifics underlying these interactions are 
currently unclear (43). The AAV genomes are then circularized and concatemerized (44) by 
DNA recombination events.
Recently, it has been shown that AAV capsid proteins might play a role in both second-
strand DNA synthesis and subsequent transcription after capsid uncoating (45). These 
observations are corroborated in part by the observation that the AAV capsid might not 
disassemble completely during uncoating and remains associated with the genome during 
this critical event (36). While, the exact mechanism by which the capsid might play a role in 
these steps remains unclear, it has recently been demonstrated that splicing factors can bind 
the exposed genome and the capsid cooperatively to block transcription (46). Specifically, 
knockdown of the splicing factors PHF5A or SF3B1, components of the U2 snRNP greatly 
augmented AAV transduction. Furthermore, both of these factors were shown to interact 
with AAV capsids, indicating a direct interaction between the cellular splicing machinery 
and AAV.
Strategies to Augment rAAV Transduction
Growing insight into how the AAV capsid and genome interact with different cellular host 
factors has led to development of diverse strategies to enhance the potency of rAAV vectors. 
The ultimate goal of these strategies is to reduce the effective vector dose needed for 
efficient transgene expression. These approaches to enhance AAV transduction range from 
agents that amplify/inhibit the function of host factors that have been implicated in AAV 
trafficking to capsid modifications that can augment transduction.
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It has been hypothesized that the proteasome plays a strong inhibitory role in rAAV 
transduction by ubiquitin-dependent degradation of capsids before they can traffic to the 
nucleus. This hypothesis is supported by several studies, the first of which demonstrated a 
large increase in transduction of rAAV2 when cells were treated with the proteasome 
inhibitor MG132 (19). Since then, several more studies have shown an increase with other 
proteasome inhibitors, namely LLnL, bortezomib (Velcade®), and carfilzomib (47–50). 
Additionally, it has been shown that rAAV2 and rAAV5 capsids are a substrate for ubiquitin 
conjugation (47), which is often a tag for proteasome-dependent degradation. Further, we 
have shown that inhibition of all cellular ubiquitination events with the UBEA1 inhibitor 
PYR-41 increases transduction (21). However, it should be noted that inhibition of ubiquitin-
dependent capsid degradation by the proteasome might only account in part for the entire 
transduction increase witnessed. For instance, it is known that bortezomib can have non-
proteasomal targets, such as serine proteases (51).
Several studies indicate the involvement of both proteotoxic stress and ER stress as cellular 
responses that occur during proteasome inhibition. Indeed, several other approaches that 
induce these stress responses also increase rAAV transduction. Cellular heat shock (52), 
chemical inhibition of Hsp90 (a molecular chaperone) (18), and increased oxygen free 
radicals (53), all induce an ER or proteotoxic stress response, and have been shown to 
increase rAAV transduction to a similar extent. Additionally, as mentioned earlier, we have 
recently demonstrated that modification of the intracellular trafficking of rAAV2 by the 
ERAD inhibitor EerI increases transduction (21). Interestingly, EerI has been shown to 
induce the ER stress response, but it is currently unknown, whether the trafficking changes 
observed are a direct result of this cellular stress (54, 55).
Another set of strategies being investigated involve modification of the AAV capsid and/or 
genome to increase transduction. One successful example of this approach is mutagenesis of 
tyrosine residues on the capsid surface to phenylalanine residues. It has been postulated that 
tyrosine residues on the capsid surface act as sites for phosphorylation and subsequent 
signaling motifs for ubiquitination, therefore leading to capsid degradation. The resulting 
Try-Phe (Y-F) mutations resulted in rAAV capsids that showed marked increase in 
transduction (56–59). Another strategy used to increase AAV transduction is modification of 
the viral genome. As previously mentioned, second-strand synthesis has been shown to be a 
major rate-limiting step in AAV transduction. Knowledge of this bottleneck led to the 
development of self-complementary AAV (scAAV) vectors, which are discussed in detail 
elsewhere (60).
In conclusion, studies aimed at understanding the intracellular trafficking pathways of 
rAAVs have provided a wealth of information that has been able to inform clinical and 
experimental approaches to gene delivery. However, our knowledge of AAV transduction 
mechanisms continues to evolve and there is a need to increase the percentage of infectious 
AAV particles that enter the nucleus and mediate robust transgene expression. Leveraging 
our understanding of rAAV cellular trafficking and structure could yield improved vectors 
with higher potency and/or lead to the development of adjuvant-based strategies to enhance 
AAV transduction.
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Highlights
• AAV exploits a spectrum of endocytic pathways after cellular uptake.
• AAV trafficking through the trans-Golgi network precedes nuclear 
entry.
• Second strand synthesis is a rate limiting step in AAV transduction.
• Strategies to circumvent AAV interactions with host restriction factors 
can help augment transduction.
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Figure 1. 
Summary of different intracellular trafficking events leading to successful AAV 
transduction. (A) Cellular internalization of AAV vectors can occur through different 
endocytic cargo uptake mechanisms. (B) Following uptake, AAV traffics through 
endolysosomal vesicles and the trans-Golgi network. (C) AAV capsid processing within 
vesicular and Golgi compartments are thought to prime the AAV capsid for nuclear entry. 
(D) Nuclear entry of AAV capsids mediated by importin is followed by capsid uncoating, 
genome release and interaction with the cellular transcriptional machinery.
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